Wolfe Research Has Bearish Forecast for Teleflex Q4 Earnings

Wolfe Research has lowered its Q4 2025 earnings estimates for Teleflex from $3.89 to $3.84 per share. Other analysts have also downgraded the stock, with price targets reduced by Wells Fargo and Royal Bank of Canada. Teleflex's stock has a consensus rating of 'Reduce' and an average target price of $134.57. The company recently reported better-than-expected quarterly earnings and declared a quarterly dividend. Institutional investors have been adjusting their holdings in the company.

Teleflex Incorporated (NYSE:TFX - Free Report) - Research analysts at Wolfe Research reduced their Q4 2025 earnings estimates for Teleflex in a research note issued to investors on Wednesday, November 12th. Wolfe Research analyst M. Polark now forecasts that the medical technology company will post earnings per share of $3.84 for the quarter, down from their prior forecast of $3.89. The consensus estimate for Teleflex's current full-year earnings is $13.98 per share. Wolfe Research also issued estimates for Teleflex's FY2029 earnings at $21.27 EPS.

Other research analysts have also issued research reports about the company. Wall Street Zen lowered Teleflex from a "buy" rating to a "hold" rating in a report on Saturday. Wells Fargo & Company dropped their price target on Teleflex from $131.00 to $114.00 and set an "equal weight" rating for the company in a research report on Friday, November 7th. Royal Bank Of Canada cut their price target on shares of Teleflex from $135.00 to $120.00 and set a "sector perform" rating for the company in a research note on Friday, November 7th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Teleflex in a report on Thursday. Finally, Zacks Research downgraded Teleflex from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 30th. One research analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Reduce" and an average target price of $134.57.

Read Our Latest Stock Report on TFX

Teleflex Trading Down 2.3%

NYSE:TFX opened at $106.94 on Monday. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44. Teleflex has a 1 year low of $102.58 and a 1 year high of $195.47. The company has a market cap of $4.73 billion, a P/E ratio of 25.16, a P/E/G ratio of 1.79 and a beta of 1.05. The stock's fifty day moving average price is $123.84 and its two-hundred day moving average price is $122.07.

Teleflex (NYSE:TFX - Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The medical technology company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $3.38 by $0.29. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The company had revenue of $892.90 million for the quarter, compared to analysts' expectations of $892.79 million. During the same period in the prior year, the company posted $3.49 EPS. Teleflex's revenue was up 19.4% compared to the same quarter last year. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 15th. Investors of record on Friday, November 14th will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date is Friday, November 14th. Teleflex's dividend payout ratio is currently -18.50%.

Institutional Trading of Teleflex

A number of institutional investors have recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB raised its position in Teleflex by 57.9% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company's stock valued at $26,000 after purchasing an additional 77 shares during the last quarter. Thompson Investment Management Inc. raised its holdings in Teleflex by 2.1% in the 2nd quarter. Thompson Investment Management Inc. now owns 4,970 shares of the medical technology company's stock worth $588,000 after purchasing an additional 100 shares in the last quarter. CX Institutional lifted its position in shares of Teleflex by 14.7% in the 2nd quarter. CX Institutional now owns 872 shares of the medical technology company's stock worth $103,000 after purchasing an additional 112 shares during the period. Signaturefd LLC boosted its stake in shares of Teleflex by 38.3% during the 1st quarter. Signaturefd LLC now owns 433 shares of the medical technology company's stock valued at $60,000 after purchasing an additional 120 shares in the last quarter. Finally, Empirical Finance LLC increased its position in shares of Teleflex by 7.9% during the first quarter. Empirical Finance LLC now owns 1,690 shares of the medical technology company's stock valued at $234,000 after buying an additional 124 shares during the period. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

Teleflex Company Profile

(Get Free Report)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

Should You Invest $1,000 in Teleflex Right Now?

Before you consider Teleflex, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.

While Teleflex currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here